Yoganand Chillarige, MPA

Research Manager
Acumen LLC
Burlingame, United States

Disclosure information not submitted.

Presentation(s):

• Evaluation of Febrile Seizure Risk Following Ancestral Monovalent COVID-19 mRNA Vaccination Among U.S. Children Aged 2-5 Years

  Monday, August 26, 2024
  2:15 PM – 2:30 PM CEST

• Assessment of Potential Adverse Events Following the 2022–2023 Seasonal Influenza Vaccines Among U.S. Adults Aged 65 Years and Older

  Monday, August 26, 2024
  2:30 PM – 2:45 PM CEST

• Stroke Risk Following Receipt of COVID-19 Bivalent Vaccines Among U.S. Adults Aged ≥65 Years

  Monday, August 26, 2024
  6:00 PM – 6:15 PM CEST

• Added Benefit and Waning Effectiveness of a Third-Dose mRNA COVID-19 Vaccine in Community-Dwelling Medicare Beneficiaries Aged ≥65 Years in Omicron Period

  Tuesday, August 27, 2024
  8:15 AM – 8:30 AM CEST

• Effectiveness Over Time of a Complete Primary Series of the Original, Monovalent COVID-19 Vaccines Among Adults Aged 18-64 Years in the United States

  Tuesday, August 27, 2024
  9:15 AM – 9:30 AM CEST

• Events on Day Zero of Follow-Up: Considerations for Cohort Studies of Adverse Events After COVID-19 Diagnosis

  Tuesday, August 27, 2024
  1:00 PM – 1:15 PM CEST

• Risk of Neurologic or Immune-Mediated Adverse Events After COVID-19 Diagnosis in the United States

  Wednesday, August 28, 2024
  1:30 PM – 1:45 PM CEST

• Risk of Cardiovascular Adverse Events After COVID-19 Diagnosis in the United States

  Wednesday, August 28, 2024
  2:45 PM – 3:00 PM CEST